Personalized therapy of non-small cell lung cancer (NSCLC)

Advances in Experimental Medicine and Biology

Volumn 890, Issue , 2016, Pages 203-222

  Gadgeel, Shirish M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

ALK; Chemotherapy; Clinical symptoms; EGFR; Histology; Molecular markers; NSCLC; Staging

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE; AFATINIB; ANTINEOPLASTIC AGENT; AZD 4547; BEVACIZUMAB; BJ 398; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIBROBLAST GROWTH FACTOR RECEPTOR; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROTEIN SERINE THREONINE KINASE; SCATTER FACTOR RECEPTOR; SELUMETINIB; TIVANTINIB; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADJUVANT THERAPY; ADVANCED CANCER; ALK GENE; ASTHENIA; BLEEDING; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; EDEMA; ESOPHAGITIS; FGFR1 GENE; GENE FUNCTION; GENE REARRANGEMENT; GENE TARGETING; GENE TRANSLOCATION; GENETICS; GENOMICS; HEALTH STATUS; HEART INFARCTION; HEMOPTYSIS; HER2 GENE; HISTOPATHOLOGY; HUMAN; LUNG RESECTION; MAINTENANCE THERAPY; MET GENE; META ANALYSIS (TOPIC); MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTATION; NEUTROPENIA; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; ONSET AGE; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PI3K GENE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RET GENE; ROS1 GENE; SEX DIFFERENCE; SMOKING; STOMATITIS; TREATMENT DURATION; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS;

EID: 84951875094     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-24932-2_11     Document Type: Chapter

References (80)

1. http://www. cancer. org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed 15 Sept 2014.
2. Chute CG, Greenberg ER, Baron J et al (1985) Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 56: 2107-11.
3. Koyi H, Hillerdal G, Brandén E (2002) A prospective study of a total material of lung cancer from a county in Sweden 1997-1999: gender, symptoms, type, stage, and smoking habits. Lung Cancer 36: 9-14.
4. Buccheri G, Ferrigno D (2004) Lung cancer: clinical presentation and specialist referral time. Eur Respir J 24: 898.
5. The National Lung Screening Trial Research Team (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409.
6. Langer C, Lilenbaum R (2004) Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer. Semin Oncol 31(suppl 6): 8-15.
7. Aggarwal C, Langer CJ (2012) Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer. Curr Opin Oncol 24: 130-6.
8. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710-1717.
9. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909.
10. Butts CA, Ding K, Seymour L et al (2010) Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 28: 29-34.
11. Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncology 7: 719-727.
12. Strauss GM, Herndon JE, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26: 5043-5051.
13. Chansky K, Sculier JP, Crowley JJ et al (2009) The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4(7): 792-801.
14. Fibla JJ, Cassivi SD, Brunelli A et al (2012) Re-evaluation of the prognostic value of visceral pleura invasion in stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set. Lung Cancer 78(3): 259-262.
15. Schuchert MJ, Schumacher L, Kilic A et al (2011) Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. Ann Thorac Surg 91(4): 1059-1065.
16. Kato T, Ishikawa K, Aragaki M et al (2012) Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer 77(2): 394-400.
17. Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anticancer chemotherapy. Cancer Treat Rev 24(5): 331-344.
18. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10): 983-991.
19. Friboulet L, Olaussen KA, Pignon JP et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368: 1101-10.
20. Gadgeel SM, Bepler G (2013) Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients. Future Oncol 9: 1909-21.
21. Goss GD, O'Callaghan C, Lorimer I et al (2013) Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 31: 3320-6.
22. Kelly K, Altorki N, Eberhart E et al (2014) A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. J Clin Oncol 32: abstract 7501.
23. Chen HY, Yu SL, Chen CH et al (2007) A five-gene signature and clinical outcome in nonsmall-cell lung cancer. N Engl J Med 356(1): 11-20.
24. Kratz JR, He J, Van Den Eeden SK et al (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379(9818): 823-832.
25. Scarpaci A, Mitra P, Jarrar D et al (2013) Multimodality approach to management of stage III non-small cell lung cancer. Surg Oncol Clin N Am 22: 319-28.
26. Donington JS, Pass HI (2013) Surgical approach to locally advanced non-small cell lung cancer. Cancer J 19: 217-21.
27. Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374: 379-86.
28. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol 26: 3543-51.
29. Ceppi P, Volante M, Saviozzi S et al (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107: 1589-96.
30. Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-40.
31. Paz-Ares LG, de Marinis F, Dediu M et al (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31: 2895-902.
32. Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-9.
33. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-91.
34. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-50.
35. Reck M, von Pawel J, Zatloukal P et al (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804-9.
36. Patel JD, Socinski MA, Garon EB et al (2013) PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31: 4349-57.
37. Santos E, Martin-Zanca D, Reddy EP et al (1984) Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223: 661-4.
38. Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-31.
39. Mascaux C, Iannino N, Martin B et al (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92(1): 131-139.
40. Shepherd FA, Bourredjem A, Brambilla E et al (2012) Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. ASCO Meeting Abstracts; 30(15 suppl): 7007.
41. Tejpar S, Celik I, Schlichting M et al (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30(29): 3570-3577.
42. Janne PA, Shaw AT, Pereira J et al (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14: 38-47.
43. Nagarajan L, Louie E, Tsujimoto Y et al (1986) The human c-ros gene (ROS) is located at chromosome region 6q16-6q22. Proc Natl Acad Sci U S A 83: 6568-72.
44. Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298: 1912-34.
45. Acquaviva J, Wong R, Charest A (2009) The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 1795: 37-52.
46. Takeuchi K, Soda M, Togashi Y et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18: 378-81.
47. Bergethon A, Shaw AT, Ou SH et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-70.
48. Shaw AT, Camidge DR, Engelman JR et al (2012) Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 30: abstract 7508.
49. Gherardi E, Birchmeier W, Birchmeier C et al (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103.
50. Park S, Choi YL, Sung CO et al (2012) High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 27: 197-207.
51. Ma PC, Jagadeeswaran R, Jagadeesh S et al (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65: 1479-88.
52. Cappuzzo F, Marchetti A, Skokan M et al (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27: 1667-74.
53. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-43.
54. Turke AB, Zejnullahu K, Wu YL et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
55. Zhang YW, Staal B, Essenburg C et al (2010) MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 70: 6880-90.
56. Liu L, Shi H, Liu Y et al (2011) Synergistic effects of foretinib with HER-targeted agents in MET and HER1-or HER2-coactivated tumor cells. Mol Cancer Ther 10: 518-30.
57. Spigel DR, Edelman MJ, O'Byrne K et al (2014) Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 32: abstract 8000.
58. Sequist LV, von Pawel J, Garmey EG et al (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29: 3307-15.
59. Camidge DR, Ou, SH, Shapiro G et al (2014) Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32: abstract 8001.
60. Gordon MS, Vogelzang NJ, Schoffski P et al (2011) Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized phase II discontinuation trial in patients with advanced solid tumors. J Clin Oncol 29: abstract 3010.
61. Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA (2003) RET and NTRK1 protooncogenes in human diseases. J Cell Physiol 195: 168-86.
62. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA (1998) RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 4: 223-8.
63. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK et al (2012) A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22: 436-45.
64. Drilon A, Wang L, Hasanovic A et al (2013) Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3: 630-5.
65. Mazieres J, Peters S, Lepage B et al (2013) Lung cancer that harbors a HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31: 1997-2003.
66. Arcila ME, Chaft JE, Nafa K et al (2012) Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 18: 4910-8.
67. Pelligrini C, Falleni M, Marchetti A et al (2003) HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 9: 3645-52.
68. Hirsch FR, Varella-Garcia M, Franklin WA et al (2002) Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung cancer. B J Cancer 86: 1449-56.
69. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-54.
70. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-16.
71. Paik PK, Arcila ME, Fara M et al (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29: 2046-51.
72. Marchetti A, Felicioni L, Malatesta S et al (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29: 3574-3579.
73. Kobayashi M, Sonobe M, Takahashi T et al (2011) Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Anticancer Res 31: 4619-23.
74. Planchard D, Mazieres J, Riely GJ et al (2013) Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 31: abstract 8009.
75. Weiss J, Sos ML, Seidel D et al (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2(62): 62ra93.
76. Heist RS, Mino-Kenudson M, Sequist LV et al (2012) FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 7: 1775-1780.
77. Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of sqaumous cell lung cancer. Nature 489: 519-25.
78. Gadgeel SM, Chen W, Cote ML et al (2013) Fibrobalst growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real time PCR. PLoS One 8: e79820.
79. Nogova L, Sequist L, Cassier PA et al (2014) Targeting FGFR-1 amplified lung squamous cell carcinoma with selective pan-FGFR inhibitor BGJ398. J Clin Oncol 32: abstract 8034.
80. Paik PK, Shen R, Ferry D et al (2014) A phase Ib open label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. J Clin Oncol 32: abstract 8035.